« Return to News | CROs/Service Providers | Drug Sponsors

Charles River Labs, AstraZeneca enter strategic partnership

Monday, October 22, 2012 10:43 AM

AstraZeneca, a global biopharmaceutical company, has selected Charles River Laboratories International, a global provider of research products and services, as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

“We are extremely pleased that AstraZeneca selected Charles River as its strategic in vivo biology partner,” said James C. Foster, chairman, president and CEO of Charles River. “Utilizing our capabilities will enable AstraZeneca to create a flexible research platform to deliver innovative health solutions. Our shared passion for scientific excellence is a strong foundation for this relationship.”

The three-year agreement extends into 2015. AstraZeneca began the process of transferring programs to Charles River earlier this year and the process is expected to be completed by early 2013. In 2013, the incremental sales under this agreement are expected to contribute approximately 1% to Charles River’s total net sales.

“Tapping into the high quality drug development services of a trusted strategic partner enables AstraZeneca to increase our resource flexibility while simplifying the way we work,” said Stefan Platz, vice president of global safety assessment, AstraZeneca. “We are pleased to partner with Charles River to utilize their scientific expertise, such as their customized in vivo biology program. Our organizations will work hand-in-hand to deliver toxicology, safety pharmacology and development DMPK studies in support of our efforts to deliver safe and effective new treatments to patients more efficiently.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.